Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: Involvement of Akt, NF-κB and Bcl-2

Toxicology and Applied Pharmacology

Volumn 216, Issue 2, 2006, Pages 177-185

  Upadhyay, Ankur Kumar ^a   Singh, Sandeep ^a   Chhipa, Rishi Raj ^a   Vijayakumar, Maleppillil Vavachan ^a   Ajay, Amrendra Kumar ^a   Bhat, Manoj Kumar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Chemotherapy; Drug uptake; Methyl cyclodextrin; Potentiation of cytotoxicity

Indexed keywords

CARBOPLATIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYL BETA CYCLODEXTRIN; PROTEIN BCL 2; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER SUSCEPTIBILITY; CELL STRAIN; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BREAST NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33749253876     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.05.009     Document Type: Article

References (37)

1. Boulikas T., and Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol. Rep. 10 (2003) 1663-1682
2. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
3. Cai C., Zhu H., and Chen J. Overexpression of caveolin-1 increases plasma membrane fluidity and reduces P-glycoprotein function in Hs578T/Dox. Biochem. Biophys. Res. Commun. 320 (2004) 868-874
4. Chen H.W., Heiniger H.J., and Kandutsch A.A. Alteration of 86Rb+ influx and efflux following depletion of membrane sterol in L-cells. J. Biol. Chem. 253 (1978) 3180-3185
5. Chhipa R.R., Singh S., Surve S.V., Vijayakumar M.V., and Bhat M.K. Doxycycline potentiates antitumor effect of cyclophosphamide in mice. Toxicol. Appl. Pharmacol. 202 (2005) 268-277
6. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev., Drug Discov. 3 (2004) 1023-1035
7. Demel R.A., Kinsky S.C., Kinsky C.B., and van Deenen L.L. Effect of temperature and cholesterol on glucose permeability of liposomes prepared with natural and synthetic lecithins. Biochim. Biophys. Acta 150 (1968) 665
8. Downward J. How BAD phosphorylation is good for survival. Nat. Cell Biol. 1 (1999) 33-35
9. Elisabeth P.C.K., Patricia G.Y., Genevieve W.S., Wen B., William J.J., Michael C.P., and George H.R. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 270 (1995) 17250-17256
10. Feuillard J., Schuhmacher M., Kohanna S., Asso-Bonnet M., Ledeur F., Joubert-Caron R., Bissières P., Polack A., Bornkamm G.W., and Raphaël M. Inducible loss of NF-κB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 95 (2000) 2068-2075
11. Finkelstein A. Water and non-electrolytes permeability of lipid bilayers membrane. J. Gen. Physiol. 68 (1976) 127-135
12. Finkelstein A., and Class A. Effect of cholesterol on the water permeability of thin lipid membranes. Nature 216 (1967) 717-718
13. Florence A.T., and Jani P.U. Novel oral drug formulations. Their potential in modulating adverse effects. Drug Safety 10 3 (1994) 233-266
14. Frijlink H.W., Visser J., Hefting J.R., Oosting R., Meijer D.K., and Lerk C.F. The pharmacokinetics of beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin in the rat. Pharm. Res. 7 (1990) 1248-1252
15. Grosse P.Y., Bressolle F., and Pinguet F. Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother. Pharmacol. 40 (1997) 489-494
16. Grosse P.Y., Bressolle F., and Pinguet F. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin. Eur. J. Cancer 34 (1998) 168-174
17. Grunze M., and Deuticke B. Changes of membrane permeability due to extensive cholesterol depletion in mammalian erythrocytes. Biochim. Biophys. Acta 356 (1974) 125-130
18. Heckman C.A., Mehew J.W., and Boxer L.M. NF-kappaB activates Bcl-2 expression in t (14; 18) lymphoma cells. Oncogene 21 (2002) 3898-3908
19. Hovgaard L., and Brondsted H. Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins. Pharm. Res. 12 (1995) 1328-1332
20. Irie T., Fukunaga K., and Pitha J. Hydroxypropylcyclodextrins in parenteral use. I: Lipid dissolution and effects on lipid transfers in vitro. J. Pharm. Sci. 81 (1992) 521-523
21. Kamau S.W., Kramer S.D., Gunthert M., and Wunderli-Allenspach H. Effect of the modulation of the membrane lipid composition on the localization and function of P-glycoprotein in MDR1-MDCK cells. In Vitro Cell. Dev. Biol. Anim. 41 7 (2005) 207-216
22. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 (2002) 221-227
23. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev., Cancer 2 (2002) 301-310
24. Longley D.B., Harkin D.P., and Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev., Cancer 3 (2003) 330-338
25. Marte B.M., and Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22 (1997) 355-358
26. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6853-6866
27. Pitha J., Irie T., Sklar P.B., and Nye J.S. Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci. 43 (1988) 493-502
28. Reungpatthanaphong P., Marbeuf-Gueye C., Le Moyec L., Salerno M., and Garnier-Suillerot A. Decrease of P-glycoprotein activity in K562/ADR cells by MbetaCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts. J. Bioenerg. Biomembr. 36 6 (2004) 533-543
29. Shah M.A., and Schwartz G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7 (2001) 2168-2181
30. Singh S., and Bhat M.K. Carboplatin induces apoptotic cell death through down-regulation of constitutively active nuclear factor-kappaB in human HPV-18 E6-positive HEp-2 cells. Biochem. Biophys. Res. Commun. 318 (2004) 346-353
31. Singh S., Chhipa R.R., Vijayakumar M.V., and Bhat M.K. DNA damaging drugs-induced down-regulation of Bcl-2 is essential for induction of apoptosis in high-risk HPV-positive HEp-2 and KB cells. Cancer Lett. 236 2 (2006) 213-221
32. Smart E.J., and Anderson R.G. Alterations in membrane cholesterol that affect structure and function of caveolae. Methods Enzymol. 353 (2002) 131-139
33. Stella V.J., and Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14 5 (1997) 556-567
34. Strasser A., Huang D.C., and Vaux D.L. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim. Biophys. Acta 1333 (1997) 151-178
35. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
36. Wang C.Y., Cusack J.C., Liu R.Jr., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
37. Wang W., Cassidy J., O'Brien V., Ryan K.M., and Collie-Duguid E. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res. 64 (2004) 8167-8176